Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial

BACKGROUND: Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST). Masitinib was evaluated in patients with advanced GIST after imatinib failure or intolerance. PATIENTS AND METHODS: Prospective, multicente...

Descripción completa

Detalles Bibliográficos
Autores principales: Adenis, A., Blay, J.-Y., Bui-Nguyen, B., Bouché, O., Bertucci, F., Isambert, N., Bompas, E., Chaigneau, L., Domont, J., Ray-Coquard, I., Blésius, A., Van Tine, B. A., Bulusu, V. R., Dubreuil, P., Mansfield, C. D., Acin, Y., Moussy, A., Hermine, O., Le Cesne, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143095/
https://www.ncbi.nlm.nih.gov/pubmed/25122671
http://dx.doi.org/10.1093/annonc/mdu237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143095/
https://www.ncbi.nlm.nih.gov/pubmed/25122671
http://dx.doi.org/10.1093/annonc/mdu237

Ejemplares similares